United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 5.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 93,673 shares of the biotechnology company's stock after selling 5,736 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.21% of United Therapeutics worth $33,052,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in UTHR. Geode Capital Management LLC raised its stake in shares of United Therapeutics by 4.3% in the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company's stock worth $391,459,000 after purchasing an additional 45,566 shares during the last quarter. FMR LLC grew its holdings in United Therapeutics by 41.1% during the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock valued at $386,168,000 after purchasing an additional 314,004 shares during the period. Pacer Advisors Inc. boosted its holdings in shares of United Therapeutics by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company's stock worth $210,869,000 after acquiring an additional 30,931 shares during the period. Janus Henderson Group PLC raised its position in shares of United Therapeutics by 12.3% in the third quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company's stock worth $164,978,000 after buying an additional 50,409 shares in the last quarter. Finally, Assetmark Inc. raised its position in United Therapeutics by 56.9% during the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company's stock valued at $150,492,000 after purchasing an additional 152,249 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on UTHR shares. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, January 16th. HC Wainwright boosted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. TD Cowen increased their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a report on Monday, October 21st. The Goldman Sachs Group increased their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. Finally, Argus increased their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $382.08.

United Therapeutics Stock Performance

Shares of UTHR traded up $0.14 during trading hours on Friday, reaching $370.58. 209,344 shares of the company traded hands, compared to its average volume of 312,203. United Therapeutics Co. has a 1-year low of $211.61 and a 1-year high of $417.82. The stock has a market cap of $16.55 billion, a P/E ratio of 16.27, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. The stock's fifty day moving average is $361.93 and its 200 day moving average is $358.80.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at $960,576.75. The trade was a 79.51 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Nilda Mesa sold 255 shares of the company's stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares of the company's stock, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 121,864 shares of company stock valued at $44,516,965. 11.90% of the stock is currently owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.